Celldex Therapeutics, Inc. (CLDX) financial statements (2022 and earlier)

Company profile

Business Address 53 FRONTAGE ROAD
HAMPTON, NJ 08827
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4081946494139190290
Cash and cash equivalents39441124404272
Short-term investments369151537099147218
Other undisclosed current assets3325565
Total current assets:4111986799145196295
Noncurrent Assets
Operating lease, right-of-use asset333
Property, plant and equipment4446101311
Intangible assets, net (including goodwill)2731494915917230
Goodwill    91919
Intangible assets, net (excluding goodwill)27314949688121
Other noncurrent assets0002221
Total noncurrent assets:3438565717118843
TOTAL ASSETS:445236123156316383338
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities131088213026
Accounts payable1111222
Accrued liabilities12867192924
Debt 12    
Other liabilities2325754
Other undisclosed current liabilities2      
Total current liabilities:17141213283530
Noncurrent Liabilities
Long-term debt and lease obligation122    
Operating lease, liability122
Liabilities, other than long-term debt7101619528317
Other liabilities7101619528317
Total noncurrent liabilities:9121719528317
Total liabilities:252629327911847
Stockholders' equity
Stockholders' equity attributable to parent41920994124236265290
Common stock0000000
Additional paid in capital1,5611,2801,1051,0841,046982879
Accumulated other comprehensive income2333332
Accumulated deficit(1,144)(1,073)(1,013)(962)(813)(719)(591)
Total stockholders' equity:41920994124236265290
TOTAL LIABILITIES AND EQUITY:445236123156316383338

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues574101375
Cost of revenue  (0)(60) (3)(1)
Cost of goods and services sold  (0)(1)   
Gross profit:573(51)1344
Operating expenses(77)(75)(58)(106)(135)(137)(134)
Other undisclosed operating income14  1  
Operating loss:(71)(63)(55)(156)(122)(133)(130)
Loss from continuing operations before equity method investments, income taxes:(71)(63)(55)(156)(122)(133)(130)
Other undisclosed income from continuing operations before income taxes12444  
Loss from continuing operations before income taxes:(71)(61)(51)(152)(117)(133)(130)
Income tax benefit01 124  
Net loss attributable to parent:(71)(60)(51)(151)(93)(133)(130)
Other undisclosed net income available to common stockholders, basic     42
Net loss available to common stockholders, diluted:(71)(60)(51)(151)(93)(129)(127)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(71)(60)(51)(151)(93)(133)(130)
Comprehensive loss:(71)(60)(51)(151)(93)(133)(130)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)(0)00052
Comprehensive loss, net of tax, attributable to parent:(71)(60)(51)(151)(93)(128)(127)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: